Attached files

file filename
8-K - 8-K - DAVITA INC.d720329d8k.htm

Exhibit 99.1

 

LOGO

Contact: Jim Gustafson

Investor Relations

DaVita HealthCare Partners Inc.

(310) 536-2585

DaVita HealthCare Partners Inc. 1st Quarter 2014 Results

Denver, Colorado, May 1, 2014 – DaVita HealthCare Partners Inc. (NYSE: DVA) today announced results for the quarter ended March 31, 2014. Income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three months ended March 31, 2014 was $183.3 million, or $0.85 per share. This compares to adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three months ended March 31, 2013 of $196.9 million, or $0.92 per share, excluding a loss contingency reserve. Income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three months ended March 31, 2013 including this item was $16.9 million, or $0.08 per share.

Financial and operating highlights include:

 

    Cash Flow: For rolling twelve months ended March 31, 2014, operating cash flow was $1.813 billion and free cash flow was $1.403 billion. For the three months ended March 31, 2014, operating cash flow was $419 million and free cash flow was $337 million. For a definition of free cash flow see Note 4 to the reconciliations of non-GAAP measures.

 

    Operating / Adjusted Operating Income: Operating income for the three months ended March 31, 2014 was $441 million. Adjusted operating income for the three months ended March 31, 2013 was $467 million, excluding a loss contingency reserve. Operating income for the three months ended March 31, 2013 including this item was $167 million.

 

    Adjusted Diluted Income from Continuing Operations: Adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. for the three months ended March 31, 2014, excluding the amortization of intangible assets associated with acquisitions, which net of tax impacts totaled $208.1 million, was $0.97 per share.

Adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. for the three months ended March 31, 2013, excluding a loss contingency reserve and amortization of intangible assets associated with acquisitions, which net of tax impacts totaled $220.8 million, was $1.03 per share.

 

    Volume: Total U.S. dialysis treatments for the first quarter of 2014 were 5,975,627, or 78,215 treatments per day, representing a per day increase of 6.3% over the first quarter of 2013. Non-acquired treatment growth in the quarter was 5.5% over the first quarter of 2013. Normalized non-acquired treatment growth in the quarter was 5.0% over the first quarter of 2013.

The number of member months for which HCP provided capitated care during the first quarter of 2014 was approximately 2.4 million representing an increase of 6.0% as compared to the first quarter of 2013, inclusive of growth contributed from acquisitions.

 

    Effective Tax Rate: Our effective tax rate was 37.1% for the three months ended March 31, 2014. This effective tax rate is impacted by the amount of third party owners’ income attributable to non-tax paying entities. The effective tax rate attributable to DaVita HealthCare Partners Inc. was 40.5% for the three months ended March 31, 2014.

We still expect our 2014 effective tax rate attributable to DaVita HealthCare Partners Inc. to be in the range of 40.0% to 41.0%.

 

    Center Activity: As of March 31, 2014, we provided dialysis services to a total of approximately 170,000 patients at 2,173 outpatient dialysis centers, of which 2,098 centers are located in the United States and 75 centers are located in ten countries outside of the United States. During the first quarter of 2014, we opened a total of 24 new dialysis centers and acquired one dialysis center in the United States. We also acquired one dialysis center and opened one new dialysis center outside of the United States.

 

1


Outlook

 

    We are updating our consolidated operating income guidance for 2014 to now be in the range of $1.725 billion to $1.840 billion. Our previous consolidated operating income guidance for 2014 was in the range of $1.725 billion to $1.860 billion.

 

    We are also updating our operating income guidance for our dialysis services and related ancillary businesses including our corporate level expenses, which we refer to as Kidney Care, for 2014 to now be in the range of $1.520 billion to $1.580 billion. Our previous operating income guidance for Kidney Care for 2014 was in the range of $1.475 billion to $1.550 billion.

 

    We are lowering our operating income for HCP for 2014 to now be in the range of $205 million to $260 million. Our previous operating income guidance for HCP for 2014 was in the range of $250 million to $310 million.

 

    We still expect our consolidated operating cash flow for 2014 to be in the range of $1.450 billion to $1.550 billion.

These projections and the underlying assumptions involve significant risks and uncertainties, including those described below and actual results may vary significantly from these current projections. Our consolidated operating cash flow amounts for 2014 exclude any potential payment relating to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations.

We will be holding a conference call to discuss our results for the first quarter ended March 31, 2014 on May 1, 2014 at 5:00 p.m. Eastern Time. The dial in number for the U.S. is (888) 950-9401 and for international is (517) 308-9354. A replay of the conference call will be available on DaVita’s official web page, www.davitahealthcarepartners.com, for the following 30 days.

 

2


This release contains forward-looking statements within the meaning of the federal securities laws, including statements related to our guidance and expectations for our 2014 consolidated operating income, our 2014 Kidney Care operating income, HCP’s 2014 operating income, our 2014 consolidated operating cash flows and our 2014 effective tax rate attributable to DaVita HealthCare Partners Inc. Factors that could impact future results include the uncertainties associated with the risk factors set forth in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2013, our subsequent quarterly and annual reports and our current reports on Form 8-K. The forward-looking statements should be considered in light of these risks and uncertainties.

These risks and uncertainties include, but are not limited to, and are qualified in their entirety by reference to the full text of those risk factors in our SEC filings relating to:

 

    the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number of patients under such plans, which may result in the loss of revenues or patients,

 

    a reduction in government payment rates under the Medicare End Stage Renal Disease program or other government-based programs,

 

    the impact of health care reform legislation that was enacted in the United States in March 2010,

 

    the impact of the Center for Medicare and Medicaid Services (CMS) 2014 Medicare Advantage benchmark structure,

 

    the impact of the American Taxpayer Relief Act,

 

    the impact of disruptions in federal government operations and funding,

 

    changes in pharmaceutical or anemia management practice patterns, payment policies, or pharmaceutical pricing,

 

    legal compliance risks, including our continued compliance with complex government regulations and current or potential investigations by various government entities and related government or private-party proceedings, including risks relating to the resolution of the 2010 and 2011 U.S. Attorney Physician Relationship Investigations, such as restrictions on our business and operations required by a corporate integrity agreement and other settlement terms, and the financial impact thereof,

 

    our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector, that may erode our patient base and reimbursement rates,

 

    our ability to complete acquisitions, mergers or dispositions that we might be considering or announce, or to integrate and successfully operate any business we may acquire or have acquired, including HCP, or to expand our operations and services to markets outside the United States,

 

    the risk that we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, yet we might not be able to operate them profitably anytime soon, if at all,

 

    risks arising from the use of accounting estimates, judgments and interpretations in our financial statements,

 

    the risk that the cost of providing services under HCP’s agreements may exceed our compensation,

 

    the risk that reductions in reimbursement rates, including Medicare Advantage rates, and future regulations may negatively impact HCP’s business, revenue and profitability,

 

    the risk that HCP may not be able to successfully establish a presence in new geographic regions or successfully address competitive threats that could reduce its profitability,

 

    the risk that a disruption in HCP’s healthcare provider networks could have an adverse effect on HCP’s business operations and profitability,

 

    the risk that reductions in the quality ratings of health maintenance organization plan customers of HCP could have an adverse effect on HCP’s business, or

 

    the risk that health plans that acquire health maintenance organizations may not be willing to contract with HCP or may be willing to contract only on less favorable terms.

We base our forward-looking statements on information currently available to us at the time of this release, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

This release contains non-GAAP financial measures. For reconciliations of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see the attached reconciliation schedules. For the reasons stated in the reconciliation schedules, we believe our presentation of non-GAAP financial measures provides useful supplemental information for investors.

 

3


DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(dollars in thousands, except per share data)

 

     Three months ended
March 31,
 
     2014     2013  

Patient service revenues

   $ 2,114,098      $ 1,979,873   

Less: Provision for uncollectible accounts

     (83,197     (70,057
  

 

 

   

 

 

 

Net patient service revenues

     2,030,901        1,909,816   

Capitated revenues

     787,565        762,615   

Other revenues

     224,310        157,151   
  

 

 

   

 

 

 

Total net revenues

     3,042,776        2,829,582   
  

 

 

   

 

 

 

Operating expenses and charges:

    

Patient care costs and other costs

     2,179,772        1,960,891   

General and administrative

     284,061        284,410   

Depreciation and amortization

     142,579        125,909   

Provision for uncollectible accounts

     2,511        878   

Equity investment income

     (7,372     (9,367

Loss contingency reserve

     —          300,000   
  

 

 

   

 

 

 

Total operating expenses and charges

     2,601,551        2,662,721   
  

 

 

   

 

 

 

Operating income

     441,225        166,861   

Debt expense

     (106,335     (105,817

Other income, net

     1,698        598   
  

 

 

   

 

 

 

Income from continuing operations before income taxes

     336,588        61,642   

Income tax expense

     124,851        15,144   
  

 

 

   

 

 

 

Income from continuing operations

     211,737        46,498   

Discontinued operations:

    

Loss from operations of discontinued operations, net of tax

     —          (139

Gain on disposal of discontinued operations, net of tax

     —          13,375   
  

 

 

   

 

 

 

Net income

     211,737        59,734   

Less: Net income attributable to noncontrolling interests

     (28,448     (29,570
  

 

 

   

 

 

 

Net income attributable to DaVita HealthCare Partners Inc.

   $ 183,289      $ 30,164   
  

 

 

   

 

 

 

Earnings per share:

    

Basic income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

   $ 0.87      $ 0.08   
  

 

 

   

 

 

 

Basic net income per share attributable to DaVita HealthCare Partners Inc.

   $ 0.87      $ 0.14   
  

 

 

   

 

 

 

Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

   $ 0.85      $ 0.08   
  

 

 

   

 

 

 

Diluted net income per share attributable to DaVita HealthCare Partners Inc.

   $ 0.85      $ 0.14   
  

 

 

   

 

 

 

Weighted average shares for earnings per share:

    

Basic

     211,375,232        208,968,952   
  

 

 

   

 

 

 

Diluted

     216,118,922        214,127,266   
  

 

 

   

 

 

 

Amounts attributable to DaVita HealthCare Partners Inc.:

    

Income from continuing operations

   $ 183,289      $ 16,915   

Discontinued operations

     —          13,249   
  

 

 

   

 

 

 

Net income

   $ 183,289      $ 30,164   
  

 

 

   

 

 

 

 

4


DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(unaudited)

(dollars in thousands)

 

     Three months ended
March 31,
 
     2014     2013  

Net income

   $ 211,737      $ 59,734   
  

 

 

   

 

 

 

Other comprehensive income (loss), net of tax:

    

Unrealized losses on interest rate swap and cap agreements:

    

Unrealized losses on interest rate swap and cap agreements

     (2,505     (2,369

Reclassifications of net swap and cap agreements realized losses into net income

     3,359        2,507   

Unrealized gains on investments:

    

Unrealized gain on investments

     331        618   

Reclassification of net investment realized gains into net income

     (207     (94

Foreign currency translation adjustments

     28        (2,106
  

 

 

   

 

 

 

Other comprehensive income (loss)

     1,006        (1,444
  

 

 

   

 

 

 

Total comprehensive income

     212,743        58,290   

Less: Comprehensive income attributable to noncontrolling interests

     (28,448     (29,570
  

 

 

   

 

 

 

Comprehensive income attributable to DaVita HealthCare Partners Inc.

   $ 184,295      $ 28,720   
  

 

 

   

 

 

 

 

5


DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)

 

     Three months ended
March 31,
 
     2014     2013  

Cash flows from operating activities:

    

Net income

   $ 211,737      $ 59,734   

Adjustments to reconcile net income to cash provided by operating activities:

    

Loss contingency reserve

     —          300,000   

Depreciation and amortization

     142,565        125,756   

Stock-based compensation expense

     15,074        16,021   

Tax benefits from stock award exercises

     22,978        9,368   

Excess tax benefits from stock award exercises

     (18,336     (6,957

Deferred income taxes

     8,902        (111,331

Equity investment income, net

     (187     (2,486

Other non-cash (income) charges and loss on disposal of assets

     8,346        (11,396

Changes in operating assets and liabilities, other than from acquisitions and divestitures:

    

Accounts receivable

     (54,565     (92,339

Inventories

     (12,280     2,162   

Other receivables and other current assets

     (17,740     (32,281

Other long-term assets

     1,418        (9,865

Accounts payable

     (42,558     (83,896

Accrued compensation and benefits

     23,570        (3,790

Other current liabilities

     20,615        79,277   

Income taxes

     92,905        93,401   

Other long-term liabilities

     16,663        47,829   
  

 

 

   

 

 

 

Net cash provided by operating activities

     419,107        379,207   
  

 

 

   

 

 

 

Cash flows from investing activities:

    

Additions of property and equipment, net

     (126,562     (116,724

Acquisitions

     (67,857     (91,498

Proceeds from asset and business sales

     56        62,357   

Purchase of investments available for sale

     (1,824     (1,212

Purchase of investments held-to-maturity

     (2,511     (4

Proceeds from sale of investments available for sale

     1,262        1,091   

Proceeds from sale of investments held to maturity

     1,508        —     

Purchase of intangible assets

     (11     (137

Distributions received on equity investments

     146        116   
  

 

 

   

 

 

 

Net cash used in investing activities

     (195,793     (146,011
  

 

 

   

 

 

 

Cash flows from financing activities:

    

Borrowings

     16,179,463        16,797,510   

Payments on long-term debt and other financing costs

     (16,244,613     (16,861,197

Distributions to noncontrolling interests

     (33,147     (34,926

Stock award exercises and other share issuances, net

     3,450        5,833   

Excess tax benefits from stock award exercises

     18,336        6,957   

Contributions from noncontrolling interests

     13,625        14,257   

Proceeds from sales of additional noncontrolling interests

     761        4,174   
  

 

 

   

 

 

 

Net cash used in financing activities

     (62,125     (67,392

Effect of exchange rate changes on cash and cash equivalents

     631        119   
  

 

 

   

 

 

 

Net increase in cash and cash equivalents

     161,820        165,923   

Cash and cash equivalents at beginning of the year

     946,249        533,748   
  

 

 

   

 

 

 

Cash and cash equivalents at end of the year

   $ 1,108,069      $ 699,671   
  

 

 

   

 

 

 

Supplemental cash flow information:

    

Non-cash investing and financing activities:

    

Fixed assets under capital lease obligations

   $ 11,918      $ 13,594   
  

 

 

   

 

 

 

 

 

6


DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(dollars in thousands, except per share data)

 

     March 31,
2014
    December 31,
2013
 
ASSETS     

Cash and cash equivalents

   $ 1,108,069      $ 946,249   

Short-term investments

     8,080        6,801   

Accounts receivable, less allowance of $247,108 and $237,143

     1,539,728        1,485,163   

Inventories

     101,173        88,805   

Other receivables

     374,017        349,090   

Other current assets

     169,628        176,414   

Income tax receivable

     —          10,315   

Deferred income taxes

     406,538        409,441   
  

 

 

   

 

 

 

Total current assets

     3,707,233        3,472,278   

Property and equipment, net of accumulated depreciation of $1,857,718 and $1,778,259

     2,224,439        2,189,411   

Intangibles, net of accumulated amortization of $530,540 and $483,773

     2,025,822        2,024,373   

Equity investments

     40,727        40,686   

Long-term investments

     81,033        79,557   

Other long-term assets

     76,909        79,598   

Goodwill

     9,242,179        9,212,974   
  

 

 

   

 

 

 
   $ 17,398,342      $ 17,098,877   
  

 

 

   

 

 

 
LIABILITIES AND EQUITY     

Accounts payable

   $ 392,907      $ 435,465   

Other liabilities

     486,565        464,422   

Accrued compensation and benefits

     629,669        603,013   

Medical payables

     284,759        287,452   

Loss contingency reserve

     397,000        397,000   

Current portion of long-term debt

     292,220        274,697   

Income tax payable

     83,054        —     
  

 

 

   

 

 

 

Total current liabilities

     2,566,174        2,462,049   

Long-term debt

     8,071,622        8,141,231   

Other long-term liabilities

     407,288        380,337   

Deferred income taxes

     822,842        812,419   
  

 

 

   

 

 

 

Total liabilities

     11,867,926        11,796,036   

Commitments and contingencies

    

Noncontrolling interests subject to put provisions

     692,780        697,300   

Equity:

    

Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued)

    

Common stock ($0.001 par value, 450,000,000 shares authorized; 214,045,116 and 213,163,248 shares issued and outstanding at March 31, 2014 and at December 31, 2013, respectively)

     214        213   

Additional paid-in capital

     1,113,714        1,070,922   

Retained earnings

     3,547,278        3,363,989   

Accumulated other comprehensive loss

     (1,639     (2,645
  

 

 

   

 

 

 

Total DaVita HealthCare Partners Inc. shareholders’ equity

     4,659,567        4,432,479   

Noncontrolling interests not subject to put provisions

     178,069        173,062   
  

 

 

   

 

 

 

Total equity

     4,837,636        4,605,541   
  

 

 

   

 

 

 
   $ 17,398,342      $ 17,098,877   
  

 

 

   

 

 

 

 

7


DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA

(unaudited)

(dollars in millions, except for per share and per treatment data)

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

1. Consolidated Financial Results:

      

Consolidated net revenues

   $ 3,043      $ 3,063      $ 2,830   

Operating income

   $ 441.2      $ 484.2      $ 166.9   

Operating income margin

     14.5     15.8     5.9

Operating income excluding a loss contingency reserve(1)

   $ 441.2      $ 484.2      $ 466.9   

Operating income margin excluding a loss contingency reserve(1)

     14.5     15.8     16.5

Income from continuing operations attributable to DaVita HealthCare Partners Inc.

   $ 183.3      $ 212.3      $ 16.9   

Income from continuing operations attributable to DaVita HealthCare Partners Inc. excluding a loss contingency reserve, net of related tax(1)

   $ 183.3      $ 212.3      $ 196.9   

Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

   $ 0.85      $ 0.99      $ 0.08   

Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. excluding a loss contingency reserve, net of related tax(1)

   $ 0.85      $ 0.99      $ 0.92   

2. Consolidated Business Metrics:

      

Expenses

      

General and administrative expenses as a percent of consolidated net revenues(2)

     9.3     10.4     10.1

Consolidated effective tax rate

     37.1     35.7     24.6

Consolidated effective tax rate attributable to DaVita HealthCare Partners Inc.(1)

     40.5     39.0     47.1

Adjusted consolidated effective tax rate attributable to DaVita HealthCare Partners Inc.(1)

     40.5     39.0     40.7

3. Summary of Division Financial Results:

      

Net revenues

      

Kidney Care:

      

Net dialysis and related lab services revenues

   $ 1,958      $ 2,007      $ 1,852   

Net ancillary services and strategic initiatives revenues, including international dialysis operations

     257        242        184   

Elimination of intersegment revenues

     (13     (15     (10
  

 

 

   

 

 

   

 

 

 

Total kidney care net revenues

     2,202        2,234        2,026   

Net HCP revenues

     841        829        804   
  

 

 

   

 

 

   

 

 

 

Total net consolidated revenues

   $ 3,043      $ 3,063      $ 2,830   
  

 

 

   

 

 

   

 

 

 

Operating income

      

Kidney Care:

      

Dialysis and related lab services operating income

   $ 387      $ 408      $ 85   

Other – Ancillary services and strategic initiatives, including international dialysis operations operating losses

     2        (9     (15

Corporate support and related long-term incentive compensation

     (2     (13     (11
  

 

 

   

 

 

   

 

 

 

Total kidney care operating income

     387        386        59   

HCP operating income

     54        98        108   
  

 

 

   

 

 

   

 

 

 

Total consolidated operating income

   $ 441      $ 484      $ 167   
  

 

 

   

 

 

   

 

 

 

 

8


DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA—continued

(unaudited)

(dollars in millions, except for per share and per treatment data)

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

4. Summary of Reportable Segment Financial Results:

      

Dialysis and Related Lab Services

      

Revenue:

      

Patient services revenues

   $ 2,037      $ 2,076      $ 1,916   

Provision for uncollectible accounts

     (82     (72     (67
  

 

 

   

 

 

   

 

 

 

Net patient service operating revenues

     1,955        2,004        1,849   

Other revenues

     3        3        3   
  

 

 

   

 

 

   

 

 

 

Total net operating revenues

   $ 1,958      $ 2,007      $ 1,852   
  

 

 

   

 

 

   

 

 

 

Operating expenses:

      

Patient care cost

   $ 1,323      $ 1,325      $ 1,216   

General and administrative

     155        184        169   

Depreciation and amortization

     96        93        85   

Equity investment income

     (3     (3     (3

Loss contingency reserve

     —          —          300   
  

 

 

   

 

 

   

 

 

 

Total operating expenses

     1,571        1,599        1,767   
  

 

 

   

 

 

   

 

 

 

Segment operating income

   $ 387      $ 408      $ 85   
  

 

 

   

 

 

   

 

 

 

HCP

      

Revenue:

      

HCP capitated revenues

   $ 772      $ 752      $ 746   
  

 

 

   

 

 

   

 

 

 

Patient services revenues

     58        63        57   

Provision for uncollectible accounts

     (2     (4     (3
  

 

 

   

 

 

   

 

 

 

Net patient service operating revenues

     56        59        54   
  

 

 

   

 

 

   

 

 

 

Other revenues

     13        18        4   
  

 

 

   

 

 

   

 

 

 

Total net operating revenues

   $ 841      $ 829      $ 804   
  

 

 

   

 

 

   

 

 

 

Operating expenses:

      

Patient care cost

   $ 672      $ 616      $ 595   

General and administrative

     78        78        69   

Depreciation and amortization

     42        43        38   

Equity investment income

     (5     (6     (6
  

 

 

   

 

 

   

 

 

 

Total operating expenses

     787        731        696   
  

 

 

   

 

 

   

 

 

 

Segment operating income

   $ 54      $ 98      $ 108   
  

 

 

   

 

 

   

 

 

 

5. Dialysis and Related Lab Services Business Metrics:

      

Volume

      

Treatments

     5,975,627        6,106,166        5,628,799   

Number of treatment days

     76.4        79.6        76.5   

Treatments per day

     78,215        76,711        73,579   

Per day year over year increase

     6.3     6.3     8.0

Non-acquired growth year over year

     5.5     4.7     4.3

Normalized non-acquired growth year over year

     5.0     5.2     4.4

Operating revenues before provision for uncollectible accounts

      

Dialysis and related lab services revenue per treatment

   $ 340.81      $ 340.04      $ 340.44   

Per treatment increase from previous quarter

     0.2     —          3.1

Per treatment increase from previous year

     0.1     3.0     2.4

Percent of net consolidated revenues

     64.1     65.2     65.2

 

9


DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA—continued

(unaudited)

(dollars in millions, except for per share and per treatment data)

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

5. Dialysis and Related Lab Services Business Metrics: (continued)

      

Expenses

      

Patient care costs

      

Percent of total segment operating revenues

     67.5     66.0     65.7

Per treatment

   $ 221.31      $ 216.89      $ 216.07   

Per treatment increase (decrease) from previous quarter

     2.0     (0.1 %)      1.6

Per treatment increase from previous year

     2.4     2.0     1.7

General and administrative expenses

      

Percent of total segment operating revenues

     7.9     9.2     9.1

Per treatment

   $ 26.00      $ 30.19      $ 30.10   

Per treatment (decrease) increase from previous quarter

     (13.9 %)      (0.3 %)      5.0

Per treatment (decrease) increase from previous year

     (13.6 %)      5.3     (0.2 %) 

Accounts receivable

      

Net receivables

   $ 1,168      $ 1,173      $ 1,164   

DSO

     55        55        57   

Provision for uncollectible accounts as a percentage of net revenues

     4.0     3.5     3.5

6. HCP Business Metrics:

      

Capitated membership

      

Total

     795,000        764,000        742,000   

Member months

     2,373,000        2,288,300        2,239,400   

Capitated revenues by sources

      

Commercial revenues

   $ 187      $ 183      $ 182   

Senior revenues

     565        550        552   

Medicaid revenues

     20        19        12   
  

 

 

   

 

 

   

 

 

 

Total capitated revenues

   $ 772      $ 752      $ 746   
  

 

 

   

 

 

   

 

 

 

Other

      

Total care dollars under management(1)

   $ 1,083      $ 1,045      $ 1,042   

Ratio of operating income to total care dollars under management

     5.0     9.4     10.4

Full time clinicians

     1,129        1,120        1,069   

IPA primary care physicians

     3,337        3,119        2,845   

7. Cash Flow:

      

Operating cash flow

   $ 419.1      $ 354.2      $ 379.2   

Operating cash flow, last twelve months

   $ 1,813.2      $ 1,773.3      $ 1,148.2   

Free cash flow(1)

   $ 336.6      $ 205.2      $ 298.9   

Free cash flow, last twelve months(1)

   $ 1,403.3      $ 1,365.5      $ 764.3   

Capital expenditures:

      

Routine maintenance/IT/other

   $ 49.3      $ 109.4      $ 45.4   

Development and relocations

   $ 77.2      $ 108.7      $ 71.3   

Acquisition expenditures

   $ 67.9      $ 75.6      $ 91.5   

 

10


DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA—continued

(unaudited)

(dollars in millions, except for per share and per treatment data)

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

8. Debt and Capital Structure:

      

Total debt(3)

   $ 8,381      $ 8,434      $ 8,526   

Net debt, net of cash and cash equivalents(3)

   $ 7,273      $ 7,488      $ 7,826   

Leverage ratio (see calculation on page 12)

     2.98x        3.06x        3.41x   

Overall weighted average effective interest rate during the quarter

     4.89     4.87     4.76

Overall weighted average effective interest rate at end of the quarter

     4.87     4.86     4.79

Weighted average effective interest rate on the Senior Secured Credit Facilities at end of the quarter

     4.19     4.18     4.09

Fixed and economically fixed interest rates as a percentage of our total debt(4)

     60     60     61

Fixed and economically fixed interest rates, including our interest rate cap agreements, as a percentage of our total debt(4)

     93     93     93

9. Clinical: (quarterly averages)

      

Dialysis adequacy -% of patients with Kt/V > 1.2 at the end of the quarter

     98     98     98

Dialysis patients with arteriovenous fistulas placed

     72     72     71

 

(1) These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see attached reconciliation schedules.
(2) Consolidated percentages of revenues are comprised of the dialysis and related lab services business, HCP’s business and other ancillary services and strategic initiatives. General and administrative expenses also includes other certain corporate support and related long-term incentive compensation.
(3) The reported balance sheet amounts at March 31, 2014, December 31, 2013, and March 31, 2013, exclude $16.7 million, $17.7 million and $20.6 million, respectively, of debt discounts associated with our Term Loan B and Term Loan B-2.
(4) The Term Loan B and Term Loan B-2 are subject to LIBOR floors of 1.50% and 1.00%, respectively. Because actual LIBOR, for all periods presented above, was lower than either of these embedded LIBOR floors, the interest rates on the Term Loan B and the Term Loan B-2 are set at their respective floors. At such time as the actual LIBOR-based variable component of our interest rate exceeds 1.50% on the Term Loan B and 1.00% on the Term Loan B-2, we will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of our interest rate on all of the Term Loan B, as well as for the Term Loan B-2. However, we are limited to a maximum rate of 2.50% on $1.25 billion of outstanding principal debt on the Term Loan B and $1.49 billion of outstanding principal debt on the Term Loan B-2 as a result of interest rate cap agreements. The remaining $443 million outstanding principal balance of the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 1.50%. The remaining $144 million outstanding principal balance of the Term Loan B-2 is subject to LIBOR-based interest rate volatility above a floor of 1.00%.

 

11


DAVITA HEALTHCARE PARTNERS INC.

SUPPLEMENTAL FINANCIAL DATA—continued

(unaudited)

(dollars in thousands)

Note 1: Calculation of the Leverage Ratio

Under the Senior Secured Credit Facilities (Credit Agreement), the leverage ratio is defined as all funded debt plus the face amount of all letters of credit issued, minus cash and cash equivalents, divided by “Consolidated EBITDA”. The leverage ratio determines the interest rate margin payable by the Company for its Term Loan A and revolving line of credit under the Credit Agreement by establishing the margin over the base interest rate (LIBOR) that is applicable. The following leverage ratio was calculated using “Consolidated EBITDA” as defined in the Credit Agreement. The calculation below is based on the last twelve months of “Consolidated EBITDA”, pro forma for routine acquisitions that occurred during the period. The Company’s management believes the presentation of “Consolidated EBITDA” is useful to investors to enhance their understanding of the Company’s leverage ratio under its Credit Agreement.

 

     Rolling twelve
months ended

March 31, 2014
 

Income from continuing operations attributable to DaVita HealthCare Partners Inc.

   $ 786,571   

Income taxes

     490,720   

Interest expense

     397,580   

Depreciation and amortization

     545,407   

Loss contingency reserve

     97,000   

Noncontrolling interests and equity investment income, net

     127,804   

Stock-based compensation

     59,051   

Other

     341   
  

 

 

 

“Consolidated EBITDA”

   $ 2,504,474   
  

 

 

 
     March 31, 2014  

Total debt, excluding debt discount of $16.7 million

   $ 8,380,556   

Letters of credit issued

     83,607   
  

 

 

 
     8,464,163   

Less: Cash and cash equivalents (less HCP’s non-guarantors’ cash)

     994,833   
  

 

 

 

Consolidated net debt

   $ 7,469,330   
  

 

 

 

Last twelve months “Consolidated EBITDA”

   $ 2,504,474   
  

 

 

 

Leverage ratio

     2.98x   
  

 

 

 

In accordance with the Credit Agreement, the Company’s leverage ratio cannot exceed 5.00 to 1.00 as of March 31, 2014. At that date the Company’s leverage ratio did not exceed 5.00 to 1.00.

 

12


DAVITA HEALTHCARE PARTNERS INC.

RECONCILIATIONS FOR NON-GAAP MEASURES

(unaudited)

(dollars in thousands except for per share data)

1. Income from continuing operations and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. excluding a loss contingency reserve, net of related tax.

We believe that income from continuing operations attributable to DaVita HealthCare Partners Inc. excluding a loss contingency reserve, net of related tax, enhances a user’s understanding of our normal income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. for these periods by providing a measure that is meaningful because it excludes an unusual amount for a loss contingency reserve related to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations and accordingly, is comparable to prior periods and indicative of consistent income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. These measures are not measures of financial performance under United States generally accepted accounting principles (GAAP) and should not be considered as an alternative to income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

Income from continuing operations attributable to DaVita HealthCare Partners Inc. excluding a loss contingency reserve, net of related tax:

 

     Three months ended  
     March 31,
2014
     December 31,
2013
     March 31,
2013
 

Income from continuing operations attributable to DaVita HealthCare Partners Inc.

   $ 183,289       $ 212,278       $ 16,915   

Add:

        

Loss contingency reserve

     —           —           300,000   

Less: Related income tax

     —           —           (120,000
  

 

 

    

 

 

    

 

 

 
   $ 183,289       $ 212,278       $ 196,915   
  

 

 

    

 

 

    

 

 

 

Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. excluding a loss contingency reserve, net of tax:

 

     Three months ended  
     March 31,
2014
     December 31,
2013
     March 31,
2013
 

Diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

   $ 0.85       $ 0.99       $ 0.08   

Add:

        

Loss contingency reserve

     —           —           0.84   
  

 

 

    

 

 

    

 

 

 
   $ 0.85       $ 0.99       $ 0.92   
  

 

 

    

 

 

    

 

 

 

 

13


DAVITA HEALTHCARE PARTNERS INC.

RECONCILIATIONS FOR NON-GAAP MEASURES – (continued)

(unaudited)

(dollars in thousands except for per share data)

 

In addition, we have excluded amortization of intangible assets associated with acquisitions from our adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. and from our adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. as we believe this presentation enhances a user’s understanding of our operating results for these periods by providing a different reflection of the Company’s operating performance since it excludes the amortization of intangible assets that relate to the remeasurement of acquired intangible assets associated with our acquisitions to fair value, and accordingly is indicative of consistent income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc. These measures are not measures of financial performance under GAAP and should not be considered as an alternative to income from continuing operations attributable to DaVita HealthCare Partners Inc. and diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

Adjusted income from continuing operations and adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc., further adjusted to exclude the amortization of intangible assets associated with acquisitions:

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

Adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc.

   $ 183,289      $ 212,278      $ 196,915   

Add:

      

Amortization of intangible assets associated with acquisitions for the dialysis and ancillary operations

     6,867        6,802        6,882   

Amortization of intangible assets associated with acquisitions for the HCP operations

     34,852        33,919        33,362   

Related income tax

     (16,896     (15,881     (16,379
  

 

 

   

 

 

   

 

 

 
   $ 208,112      $ 237,118      $ 220,780   
  

 

 

   

 

 

   

 

 

 

Adjusted diluted income from continuing operations per share attributable to DaVita HealthCare Partners Inc.

   $ 0.85      $ 0.99      $ 0.92   

Add:

      

Amortization of intangible assets per share associated with acquisitions for the dialysis and ancillary operations, net of tax

     0.02        0.02        0.02   

Amortization of intangible assets per share associated with acquisitions for the HCP operations, net of tax

     0.10        0.09        0.09   
  

 

 

   

 

 

   

 

 

 
   $ 0.97      $ 1.10      $ 1.03   
  

 

 

   

 

 

   

 

 

 

 

14


DAVITA HEALTHCARE PARTNERS INC.

RECONCILIATIONS FOR NON-GAAP MEASURES

(unaudited)

(dollars in thousands)

2. Operating income excluding a pre-tax loss contingency reserve.

We believe that operating income excluding a pre-tax loss contingency reserve, enhances a user’s understanding of our normal operating income for these periods by providing a measure that is meaningful because it excludes an unusual amount for a loss contingency reserve related to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations, and accordingly, is comparable to prior periods and indicative of consistent operating income. This measure is not a measure of financial performance under GAAP and should not be considered as an alternative to operating income.

Operating income excluding a pre-tax loss contingency reserve:

 

     Three months ended  
     March 31,
2014
     December 31,
2013
     March 31,
2013
 

Operating income

   $ 441,225       $ 484,179       $ 166,861   

Add:

        

Loss contingency reserve

     —           —           300,000   
  

 

 

    

 

 

    

 

 

 

Adjusted operating income

   $ 441,225       $ 484,179       $ 466,861   
  

 

 

    

 

 

    

 

 

 

 

15


DAVITA HEALTHCARE PARTNERS INC.

RECONCILIATIONS FOR NON-GAAP MEASURES

(unaudited)

(dollars in thousands)

 

3. Effective Income Tax Rates

We believe that reporting the effective income tax rate attributable to DaVita HealthCare Partners Inc. as well as the adjusted effective income tax rate attributable to DaVita HealthCare Partners Inc., excluding a loss contingency reserve, enhances an investor’s understanding of DaVita HealthCare Partners Inc.’s effective income tax rate and DaVita HealthCare Partners Inc.’s adjusted effective income tax rate for the periods presented because it excludes noncontrolling owners’ income that primarily relates to non-tax paying entities, and an unusual amount for a loss contingency reserve related to the 2010 and 2011 U.S. Attorney Physician Relationship Investigations, and is meaningful to an investor to fully understand the related income tax effects on DaVita HealthCare Partners Inc.’s operating results. These are not measures under GAAP and should not be considered as an alternative to the effective income tax rate calculated in accordance with GAAP.

Effective income tax rate as compared to the effective income tax rate attributable to DaVita HealthCare Partners Inc. is as follows:

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

Income from continuing operations before income taxes

   $ 336,588      $ 380,020      $ 61,642   
  

 

 

   

 

 

   

 

 

 

Income tax expense

   $ 124,851      $ 135,747      $ 15,144   
  

 

 

   

 

 

   

 

 

 

Effective income tax rate

     37.1     35.7     24.6
  

 

 

   

 

 

   

 

 

 

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

Income from continuing operations before income taxes

   $ 336,588      $ 380,020      $ 61,642   

Less: Noncontrolling owners’ income primarily attributable to non-tax paying entities

     (28,539     (32,020     (29,638
  

 

 

   

 

 

   

 

 

 

Income before income taxes attributable to DaVita HealthCare Partners Inc.

   $ 308,049      $ 348,000      $ 32,004   
  

 

 

   

 

 

   

 

 

 

Income tax expense

     124,851        135,747      $ 15,144   

Less: Income tax attributable to noncontrolling interests

     (91     (25     (68
  

 

 

   

 

 

   

 

 

 

Income tax attributable to DaVita HealthCare Partners Inc.

   $ 124,760      $ 135,722      $ 15,076   
  

 

 

   

 

 

   

 

 

 

Effective income tax rate attributable to DaVita HealthCare Partners Inc.

     40.5     39.0     47.1
  

 

 

   

 

 

   

 

 

 

Adjusted effective income tax rates attributable to DaVita HealthCare Partners Inc. excluding a loss contingency reserve:

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

Income from continuing operations before income taxes

   $ 336,588      $ 380,020      $ 61,642   

Add: Loss contingency reserve

     —          —          300,000   
  

 

 

   

 

 

   

 

 

 
     336,588        380,020        361,642   

Less: Noncontrolling owners’ income primarily attributable to non-tax paying entities

     (28,539     (32,020     (29,638
  

 

 

   

 

 

   

 

 

 

Adjusted income before income taxes attributable to DaVita HealthCare Partners Inc.

   $ 308,049      $ 348,000      $ 332,004   
  

 

 

   

 

 

   

 

 

 

Income tax expense

   $ 124,851      $ 135,747      $ 15,144   

Add: Income taxes attributable to loss contingency reserve

     —          —          120,000   

Less: Income tax attributable to noncontrolling interests

     (91     (25     (68
  

 

 

   

 

 

   

 

 

 

Adjusted income tax attributable to DaVita HealthCare Partners Inc.

   $ 124,760      $ 135,722      $ 135,076   
  

 

 

   

 

 

   

 

 

 

Adjusted effective income tax rate attributable to DaVita HealthCare Partners Inc.

     40.5     39.0     40.7
  

 

 

   

 

 

   

 

 

 

 

16


DAVITA HEALTHCARE PARTNERS INC.

RECONCILIATIONS FOR NON-GAAP MEASURES

(unaudited)

(dollars in thousands)

 

4. Free cash flow

Free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests and capital expenditures for routine maintenance and information technology. We believe free cash flow is a useful adjunct to cash flow from operating activities and other measurements under GAAP, since free cash flow is a meaningful measure of our ability to fund acquisition and development activities and meet our debt service requirements. In addition, free cash flow excluding distributions to noncontrolling interests provides an investor with an understanding of free cash flows that are attributable to DaVita HealthCare Partners Inc. Free cash flow is not a measure of financial performance under GAAP and should not be considered as an alternative to cash flows from operating, investing or financing activities, as an indicator of cash flows or as a measure of liquidity.

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

Cash provided by operating activities

   $ 419,107      $ 354,187      $ 379,207   

Less: Distributions to noncontrolling interests

     (33,147     (39,590     (34,926
  

 

 

   

 

 

   

 

 

 

Cash provided by operating activities attributable to DaVita HealthCare Partners Inc.

     385,960        314,597        344,281   

Less: Expenditures for routine maintenance and information technology

     (49,349     (109,402     (45,426
  

 

 

   

 

 

   

 

 

 

Free cash flow

   $ 336,611      $ 205,195      $ 298,855   
  

 

 

   

 

 

   

 

 

 
     Rolling 12-Month Period  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

Cash provided by operating activities

   $ 1,813,241      $ 1,773,341      $ 1,148,181   

Less: Distributions to noncontrolling interests

     (137,547     (139,326     (122,025
  

 

 

   

 

 

   

 

 

 

Cash provided by operating activities attributable to DaVita HealthCare Partners Inc.

     1,675,694        1,634,015        1,026,156   

Less: Expenditures for routine maintenance and information technology

     (272,422     (268,499     (261,812
  

 

 

   

 

 

   

 

 

 

Free cash flow

   $ 1,403,272      $ 1,365,516      $ 764,344   
  

 

 

   

 

 

   

 

 

 

 

17


DAVITA HEALTHCARE PARTNERS INC.

RECONCILIATIONS FOR NON-GAAP MEASURES

(unaudited)

(dollars in thousands)

 

5. Total care dollars under management

In California, as a result of our managed care administrative services agreement with hospitals, HCP does not assume the direct financial risk for institutional (hospital) services, but is responsible for managing the care dollars associated with both the professional (physician) and institutional services being provided for the Per Member Per Month (PMPM) fee attributable to both professional and institutional services. In those cases, HCP recognizes the surplus of institutional revenue less institutional expense as HCP net revenue. In addition to revenues recognized for financial reporting purposes, HCP measures its total care dollars under management, which includes the PMPM fee payable to third parties for institutional (hospital) services where HCP manages the care provided to its members by the hospitals and other institutions, which are not included in GAAP revenues. HCP uses total care dollars under management as a supplement to GAAP revenues as it allows HCP to measure profit margins on a comparable basis across both the global capitation model (where HCP assumes the full financial risk for all services, including institutional services) and the risk sharing models (where HCP operates under managed care administrative services agreements where HCP does not assume the full risk). HCP believes that presenting amounts in this manner is useful because it presents its operations on a unified basis without the complication caused by models that HCP has adopted in its California market as a result of various regulations related to the assumption of institutional risk. Total care dollars under management is not a measure of financial performance computed in accordance with GAAP and should not be considered in isolation or as a substitute for revenues calculated in accordance with GAAP. Total care dollars under management includes PMPM payments received from third parties that are recorded net of expenses in our accounting records. The following table reconciles total care dollars under management to medical revenues to the periods indicated.

 

     Three months ended  
     March 31,
2014
    December 31,
2013
    March 31,
2013
 

Medical revenues

   $ 827,831      $ 810,553      $ 799,674   

Less: Risk share revenue, net

     (29,558     (41,288     (39,824

Add: Institutional capitation amounts

     284,389        275,380        282,548   
  

 

 

   

 

 

   

 

 

 

Total care dollars under management

   $ 1,082,662      $ 1,044,645      $ 1,042,398   
  

 

 

   

 

 

   

 

 

 

 

18